2024年9月11日 · Alloantibody is an antibody formed in response to pregnancy, transfusion, or transplantation against an antigen not present on the person's red blood cells

2019年4月25日 · Alloantibodies may be clinically significant in future transfusion scenarios, potentially resulting in acute or delayed hemolytic transfusion reactions or in difficulty locating compatible RBC units for future transfusion.

Alloimmunity (sometimes called isoimmunity) is an immune response to nonself antigens from members of the same species, which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens [1] and histocompatibility antigens.

Alloantibodies are antibodies that are formed when an individual is exposed to an antigen that they do not express either by red cell transfusion, pregnancy, or organ transplant. You might find these chapters and articles relevant to this topic. Mark D. Stegall, James M. Gloor, in Kidney Transplantation (Sixth Edition), 2008.

Taking a close look at the physiopathology of RBC alloimmunization, it is no surprise to find a strong association between autoantibody and alloantibody development. B cells are the cornerstone of autoimmunity and are also key elements in the initiation of alloantibody production.

2016年12月2日 · Red blood cell (RBC) alloimmunization, or the formation of antibodies against non–self-antigens on RBCs, may occur after exposure through transfusion or pregnancy. These antibodies may be clinically significant in both settings, leading to delayed hemolytic or serologic transfusion reactions or hemolytic disease of the fetus and newborn (HDFN).

Alloantibody. Alloantibodies, particularly those that recognize donor HLA, can mediate hyperacute rejection, acute ABMR, and chronic ABMR.

Alloimmunization is caused by exposure to erythrocytes from a donor that expresses blood group antigens other than those of the recipient and is related to processes that alter the balance of the immune system. Knowing the pathophysiology of alloimmunization process is essential to understand clinical complications associated with this process.

2019年2月21日 · Here we provide a biochemical/biophysical and functional characterization of a human monoclonal alloantibody specific for a common HLA type, HLA-A*11:01.

Alloimmunization to non-ABO, red blood cell (RBC) antigens remains one of the most clinically-relevant complexities faced by blood banking practitioners. In the setting of transfusion therapy, these antibodies raise risks for incompatibilities, while for pregnant patients they can mediate deadly forms of hemolytic disease of the fetus and newborn.